{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:31:01Z","timestamp":1791930661158,"version":"4.3.4"},"reference-count":24,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Overexpression of CD47, a \u201cdon't eat me\u201d signal for macrophages, in various malignancies has prompted the development of anti\u2010CD47 therapies. Although the first\u2010in\u2010class anti\u2010CD47 antibody magrolimab was abandoned due to its ineffectiveness in improving survival in acute myeloid leukemia, multiple anti\u2010CD47 drugs remain in clinical trials. These agents can pose significant challenges in pre\u2010transfusion diagnostics by inducing agglutination and interfering with serological testing due to CD47 expression on red blood cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design and Methods<\/jats:title>\n                    <jats:p>This study aims to evaluate the interference caused by several anti\u2010CD47 antibodies\u2014ligufalimab, lemzoparlimab, and letaplimab\u2014and the SIRP\u03b1 IgG1 Fc fusion protein ontorpacept in pre\u2010transfusion testing and to compare their effects with magrolimab. We are also testing the mitigation of the anti\u2010CD47 drug interference by antigen masking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our results show that all drugs tested significantly interfered at clinically relevant concentrations, affecting the indirect antiglobulin test and partially also card tests without anti\u2010human globulin and Werfen's Capture\u2010R assay. Notably, a soluble recombinant SIRP\u03b1 variant, MagroEx, demonstrated efficacy in mitigating this interference in all assays tested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings emphasize the need for awareness and adaptation in immunohematology practices as anti\u2010CD47 drugs continue to advance in clinical development, and highlight the utility of antigen masking strategies to enhance the safe administration of blood products to treated patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/trf.18367","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T09:32:34Z","timestamp":1755077554000},"page":"1914-1921","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti\u2010\n                    <scp>CD47<\/scp>\n                    drug interference in pre\u2010transfusion testing can be overcome by antigen masking"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7022-0741","authenticated-orcid":false,"given":"Cora P.","family":"Habicht","sequence":"first","affiliation":[{"name":"imusyn GmbH &amp; Co. KG  Hanover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Adolph","sequence":"additional","affiliation":[{"name":"imusyn GmbH &amp; Co. KG  Hanover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gr\u00fcger","sequence":"additional","affiliation":[{"name":"imusyn GmbH &amp; Co. KG  Hanover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Hervatin","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Transfusionsmedizin und Transplant Engineering Medical School Hanover  Hanover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Immenschuh","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Transfusionsmedizin und Transplant Engineering Medical School Hanover  Hanover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Kr\u00e1lov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Blood Transfusion  Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6235-1875","authenticated-orcid":false,"given":"Clemens","family":"Schneewei\u00df","sequence":"additional","affiliation":[{"name":"imusyn GmbH &amp; Co. KG  Hanover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00018"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027222"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.943"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1348852"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1331"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115674"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00930-1"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15397"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16009"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15033"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005517"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122793"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000534273"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-2139-2189"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23414"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1285"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1187"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0328"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02018"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13150"},{"key":"e_1_2_9_22_1","first-page":"1","article-title":"Antigen masking indirect antiglobulin test can mitigate the interference of mezagitamab, a novel anti\u2010CD38 antibody, in serological pre\u2010transfusion testing","author":"Habicht CP","year":"2025","journal-title":"Transfus Med"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1139\/O10-154"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15934"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17253"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.18367","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.18367","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.18367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T07:23:33Z","timestamp":1771313013000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.18367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/trf.18367"],"URL":"https:\/\/doi.org\/10.1111\/trf.18367","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"2025-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}